Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke

RHAPSODY 试验的最终结果：一项多中心、第 2 阶段试验，采用持续重新评估方法来确定 3K3A-APC（人类活化蛋白 C 的重组变体）与组织型纤溶酶原激活剂、机械血栓切除术或两者联合用于治疗中度至重度急性缺血性中风的安全性和耐受性